Display options
Cite
Sun W, Yan H, Qian C, et al. Cofilin-1 and phosphoglycerate kinase 1 as promising indicators for glioma radiosensibility and prognosis. Oncotarget. 2017;8(33):55073-55083doi: 10.18632/oncotarget.19025.
Sun, W., Yan, H., Qian, C., Wang, C., Zhao, M., Liu, Y., Zhong, Y., Liu, H., & Xiao, H. (2017). Cofilin-1 and phosphoglycerate kinase 1 as promising indicators for glioma radiosensibility and prognosis. Oncotarget, 8(33), 55073-55083. https://doi.org/10.18632/oncotarget.19025
Sun, Wenbo, et al. "Cofilin-1 and phosphoglycerate kinase 1 as promising indicators for glioma radiosensibility and prognosis." Oncotarget vol. 8,33 (2017): 55073-55083. doi: https://doi.org/10.18632/oncotarget.19025
Sun W, Yan H, Qian C, Wang C, Zhao M, Liu Y, Zhong Y, Liu H, Xiao H. Cofilin-1 and phosphoglycerate kinase 1 as promising indicators for glioma radiosensibility and prognosis. Oncotarget. 2017 Jul 05;8(33):55073-55083. doi: 10.18632/oncotarget.19025. eCollection 2017 Aug 15. PMID: 28903403; PMCID: PMC5589642.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 05;8(33):55073-55083. doi: 10.18632/oncotarget.19025. eCollection 2017 Aug 15.

Cofilin-1 and phosphoglycerate kinase 1 as promising indicators for glioma radiosensibility and prognosis.

Oncotarget

Wenbo Sun, Hua Yan, Chunfa Qian, Chenhan Wang, Mengjie Zhao, Yuchi Liu, Yujie Zhong, Hongyi Liu, Hong Xiao

Affiliations

  1. Department of Neurosurgery, Nanjing Medical University Affiliated Brain Hospital, Nanjing, China.
  2. Department of Neuro-Psychiatric Institute, Nanjing Medical University Affiliated Brain Hospital, Nanjing, China.

PMID: 28903403 PMCID: PMC5589642 DOI: 10.18632/oncotarget.19025

Abstract

Glioma is a primary malignancy in central nervous system. Radiotherapy has been used as one of the standard treatments for glioma for decades. Since radioresistance can reduce the curative efficacy of radiotherapy in glioma, investigating the cause of radioresistance and predicting the tumour radiosensibility appeared particularly important. We previously reported that CFL1 and PGK1 are over-expressed in radioresistant U251 glioma cells. In this study, the level of CFL1 and PGK1 of 113 glioma tissues were measured by ELISA method. The relevance of the expression of these two proteins to radiosensibility was analyzed by mean test and multivariate logistic regression. The survival analysis was carried out in 85 irradiated patients and 105 followed-up patients respectively. The relationship between protein expression and clinical parameters was explored in overall 113 patients, and the correlation between CFL1 and PGK1 were determined as well. Our results showed that the expression of CFL1 and PGK1 were significantly higher (

Keywords: CFL1; PGK1; glioma; prognosis; radiosensibility

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.

References

  1. Tumour Biol. 2013 Apr;34(2):1139-44 - PubMed
  2. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112 - PubMed
  3. Proteomics. 2006 Apr;6(7):2259-72 - PubMed
  4. Int J Cancer. 2010 Mar 15;126(6):1513-20 - PubMed
  5. Hepatology. 2017 Feb;65(2):515-528 - PubMed
  6. Cancer Res. 1989 Dec 1;49(23):6449-65 - PubMed
  7. Br J Cancer. 2015 Apr 14;112(8):1332-9 - PubMed
  8. Br J Radiol. 2010 Sep;83(993):723-8 - PubMed
  9. Science. 2008 Sep 26;321(5897):1807-12 - PubMed
  10. J Cancer Res Clin Oncol. 1998;124(6):315-20 - PubMed
  11. Cancer Invest. 2013 Feb;31(2):132-9 - PubMed
  12. Cell Mol Life Sci. 2015 May;72(10):1881-92 - PubMed
  13. J Mol Biol. 2007 Feb 2;365(5):1350-8 - PubMed
  14. Cell Physiol Biochem. 2010;26(2):147-54 - PubMed
  15. Oncol Lett. 2015 Jun;9(6):2757-2761 - PubMed
  16. CNS Neurosci Ther. 2012 Sep;18(9):729-36 - PubMed
  17. Cell Signal. 2013 Feb;25(2):457-69 - PubMed
  18. Nature. 2000 Dec 14;408(6814):869-73 - PubMed
  19. Oncol Rep. 2014 Oct;32(4):1513-20 - PubMed
  20. Radiother Oncol. 2002 Sep;64(3):259-73 - PubMed
  21. Mol Med Rep. 2016 May;13(5):4414-20 - PubMed
  22. Oncol Rep. 2014 Feb;31(2):894-900 - PubMed
  23. Neurotherapeutics. 2009 Jul;6(3):447-57 - PubMed
  24. Oncotarget. 2016 Mar 1;7(9):10498-512 - PubMed
  25. Cell Cycle. 2016 Jul 17;15(14 ):1803-4 - PubMed
  26. Nat Rev Cancer. 2008 Jul;8(7):545-54 - PubMed
  27. BMC Cell Biol. 2013 Oct 05;14:45 - PubMed
  28. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13537-42 - PubMed
  29. Int J Clin Exp Pathol. 2015 May 01;8(5):5485-90 - PubMed
  30. Mol Med Rep. 2015 May;11(5):3354-60 - PubMed
  31. Int J Radiat Biol. 2009;85(10):825-36 - PubMed
  32. J Neurooncol. 2014 Sep;119(2):227-34 - PubMed
  33. Mol Cell. 2016 Mar 3;61(5):705-719 - PubMed
  34. J Mol Biol. 2016 Apr 24;428(8):1604-16 - PubMed
  35. Acta Neuropathol. 2007 Nov;114(5):443-58 - PubMed
  36. Nature. 2003 Jan 23;421(6921):436-40 - PubMed
  37. Biochim Biophys Acta. 1998 Apr 1;1397(1):102-17 - PubMed
  38. Clin Oncol (R Coll Radiol). 2007 Oct;19(8):561-71 - PubMed
  39. Mol Biol Cell. 2005 Feb;16(2):649-64 - PubMed
  40. Oncogene. 2013 Apr 25;32(17 ):2200-10 - PubMed
  41. Oncol Rep. 2016 May;35(5):2743-54 - PubMed
  42. Cancer Res. 2003 Apr 1;63(7):1602-7 - PubMed
  43. Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 - PubMed
  44. Cancer Res. 2007 Jan 1;67(1):149-59 - PubMed
  45. Oncol Rep. 2015 Jun;33(6):2807-14 - PubMed

Publication Types